Shuttle Pharmaceuticals and United Dogecoin Announce Purchase Order for up to 3,000 ElphaPex Dogecoin and Litecoin Mining Rigs
Gaithersburg, Maryland--(Newsfile Corp. - May 14, 2026) - Shuttle Pharmaceutical Holdings, Inc. (NASDAQ: SHPH) ("Shuttle" or the "Company") today announced the closing (the "Closing") of its previously announced merger with United Dogecoin Inc. ("United Dogecoin"), and the confirmation of a purchase order granting the Company the option to purchase up to 3,000 next-generation ElphaPex Scrypt mining rigs ("Mining Rigs") for use in the Company's Dogecoin (DOGE) and Litecoin (LTC) merge-mining o
2026-05-14 4:05 PM EDT | Shuttle Pharmaceuticals Holdings Inc.
Conexeu Sciences Unveils Defining Commitment: Architecting Bioregeneration(TM)
Reno, Nevada--(Newsfile Corp. - May 14, 2026) - Conexeu Sciences Inc. (the "Company" or "Conexeu") a medical device company advancing regenerative medicine through its patented bioregenerative extracellular matrix platform, today unveiled a new defining identity: Architecting Bioregeneration™.
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-05-14 8:30 AM EDT | Conexeu Sciences Inc.
Custom Health Announces Appointment of Chief Financial Officer and Board of Directors and Shareholder Approval for Proposed Public Listing
Jason Nalewany has been appointed as Chief Financial Officer of Custom Health and, following the completion of the Arrangement, the Resulting Issuer. Jason will support both companies by providing public company compliance, financial reporting, capital allocation and long-term growth strategy. The Resulting Issuer and the operations of Custom Health will be supported by an experienced Board of Directors that bring deep expertise across healthcare, technology, capital markets and
Technologies, Pharmaceutique, Santé
2026-05-14 7:00 AM EDT | Custom Health Inc.
BioHarvest Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
Quarterly revenue up 8% year over year; Annual revenue guidance range remains at $42-$48 million CDMO fragrance and Saffron projects reach successful milestones; First quarter CDMO revenue grew 135% YoY VINIA brand customer base grows to 90,000 active users as of the end of April Two-lens
Biotechnologies, Pharmaceutique, Santé
2026-05-14 7:00 AM EDT | BioHarvest Sciences Inc.
Herbal Dispatch Secures EU-GMP Processing Partnership to Accelerate German and European Export Growth
Vancouver, British Columbia--(Newsfile Corp. - May 14, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), a Canadian cannabis e-commerce and export platform, is pleased to announce that it has entered into an exclusive strategic supply agreement with a European Union Good Manufacturing Practice ("EU-GMP") licensed cannabis processor based in Portugal. The agreement establishes a long-term
Pharmaceutique, Cannabis, Dispensaires de cannabis
2026-05-14 3:01 AM EDT | Herbal Dispatch Inc.
TempraMed Announces Granted Indian Design Patent for VIVI Cap Smart Product
Highlights Granted Patent covers the design of VIVI Cap Smart™ across major international, growing market Strengthens the Company's intellectual property position in one of the world's largest healthcare and consumer markets Supports commercialization strategy and strategic discussions with appliance manufacturers Design term extends through May 16, 2039 Company enters into f
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-05-14 3:00 AM EDT | TempraMed Technologies Ltd.
Profound Medical Annual General and Special Meeting of Shareholders Voting Results
Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - Profound Medical Corp. (TSX: PRN) (NASDAQ: PROF) ("Profound" or the "Company") is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders that was held today (the "Meeting"). A total of 25,347,133 common shares, representing 69.754% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in th
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-05-13 8:41 PM EDT | Profound Medical Corp.
BioHarvest Sciences Appoints New Head of Business Development for its CDMO Division
British Columbia and Rehovot, Israel--(Newsfile Corp. - May 13, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced the appointment of Nedira Salzman-Frenkel to Vice President of Business Development. Ms. Salzman-Frenkel's role will be instrumental for sourcing and managing new prospective contracts across the pharmaceutical, nutraceu
Biotechnologies, Pharmaceutique, Santé
2026-05-13 5:32 PM EDT | BioHarvest Sciences Inc.
PharmaTher's Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus
Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company, today announced that Sairiyo Therapeutics Inc. ("Sairiyo"), a company 49% owned by PharmaTher and 51% owned by PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF), is pursuing its strategic plans to focus on the clinical development of its patented enteric-coated oral Cepharanthine ("PD-001") as a potential therapeutic candidate
Biotechnologies, Pharmaceutique
2026-05-13 10:11 AM EDT | PharmaTher Holdings Ltd.
BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director
Vancouver, British Columbia--(Newsfile Corp. - May 13, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotech company, is pleased to announce it has appointed Doug Drysdale, currently BetterLife's corporate advisor and formerly CEO of Cybin Inc. ("Cybin") (NYSE: CYBN), as Executive Chairman and Director. At Cybin, Mr. Drysdale led the company's strategy and team build-out, taking it from molecule inception to Pha
2026-05-13 8:00 AM EDT | BetterLife Pharma Inc.
BioHarvest Sciences Announces Successful Completion of Stage 1 Development of Saffron Composition for Nutraceutical and Culinary Applications
- CDMO program advances to Stage 2 of development agreement valued at $1.125 million -Advancement of sustainable solution for the production of saffron, one of the world's most valuable and health-promoting botanicals - In addition to future commercial manufacturing royalties, BioHarvest also holds a 25% ownership position in Saffron Composition Vancouver, British Colum
Biotechnologies, Pharmaceutique, Santé
2026-05-13 8:00 AM EDT | BioHarvest Sciences Inc.
PreveCeutical Closes Initial Tranche of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - May 12, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news release dated April 22, 2026, it has closed an initial tranche (the "Initial Tranche") of its previously announced $1,000,000 non-brokered private placement (the "Offering"), which Initial Tranche consisted of the issuance of 13,600,000 units (e
Biotechnologies, Pharmaceutique, Santé
2026-05-12 5:02 PM EDT | PreveCeutical Medical Inc.
DIMERx Preclinical Data Confirms DMX-101 Non-Addictive Profile: No Reinforcement, No Dependence
San Francisco, California--(Newsfile Corp. - May 12, 2026) - DIMERx, Inc. ("DIMERx" or "the Company") is a clinical-stage biopharmaceutical company dedicated to addressing the public-health crisis of drug misuse and dependence, with a portfolio of first-
Biotechnologies, Pharmaceutique, Santé
2026-05-12 9:00 AM EDT | DIMERx INC.
BioHarvest Sciences Signs $1.2M CDMO Stage 2 Contract for the Development of a Rare Fragrance Using Its Proprietary Botanical Synthesis Platform
British Columbia and Rehovot, Israel--(Newsfile Corp. - May 12, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its CDMO division has s
Biotechnologies, Pharmaceutique, Santé
2026-05-12 7:30 AM EDT | BioHarvest Sciences Inc.
Phio Pharmaceuticals Announces "Innovations in Skin Cancer Treatment and Prevention" in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - May 12, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing tec
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-05-12 7:00 AM EDT | Phio Pharmaceuticals Corp.
Herbal Dispatch Expands House of Brands Strategy with Launch of Northern Drip Extracts
Vancouver, British Columbia--(Newsfile Corp. - May 12, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company") is pleased to announce the launch of its new mid-to-premium cannabis extracts brand, Northern Drip, expanding the Company's presence in one of the fastest-growing segments of the Canadian cannabis market.Northern Drip represents Herbal Dispatch's fifth in-house brand launch, joining the Company
Pharmaceutique, Cannabis, Dispensaires de cannabis
2026-05-12 3:01 AM EDT | Herbal Dispatch Inc.
Telescope Innovations Shares Spring 2026 Conference and Events Lineup
Vancouver, British Columbia--(Newsfile Corp. - May 11, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company") is a developer of enabling technologies and services for the global pharmaceutical and high value chemical industries. The Company is pleased to report on outreach, marketing, and educational activities, both past and planned for spring 2026. Our participation includes presentations, exhibitions and keynote lect
Technologies, Produits chimiques, Pharmaceutique
2026-05-11 8:00 AM EDT | Telescope Innovations Corp.
Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
Encinitas, California--(Newsfile Corp. - May 8, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today reported financial results for the first quarter ended March 31, 2026, and provided an update on its clinical pipeline of small molecules for the treatment of retinal diseases. First Quarter 2026 and Recent Highlights Enrollment in the Phase 2 ABACUS-2 study of KIO-301 remains very active, with expansion of clinical trial sites to accommodat
Biotechnologies, Pharmaceutique
2026-05-08 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
King of Prussia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio today reported its financial results for the quarter ended March 31, 2026, and provided a busine
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-05-07 4:05 PM EDT | Phio Pharmaceuticals Corp.
Herbal Dispatch Reports Accelerating Veteran Customer Growth and Expansion of Insurance-Focused Service Channel
Vancouver, British Columbia--(Newsfile Corp. - May 7, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), is pleased to provide an update on the continued growth and expansion of its veteran-focused medical cannabis channel. The Company has experienced sustained acceleration in veteran customer acquisition, driven by targeted outreach, streamlined onboarding, and a dedicated service model tailored to the
Pharmaceutique, Cannabis, Dispensaires de cannabis
2026-05-07 7:00 AM EDT | Herbal Dispatch Inc.